Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: First histologically confirmed case

Pathology International

Volumn 56, Issue 9, 2006, Pages 530-537

  Tashiro, Yukie ^a   Goto, Masamichi ^a   Takemoto, Yoshinobu ^b   Sato, Eiichi ^a   Shirahama, Hiroshi ^a   Utsunomiya, Atae ^b   Eizuru, Yoshito ^a   Yonezawa, Suguru ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b IMAMURA BUN IN HOSPITAL   (Japan)

Author keywords

Enteritis; Epstein Barr virus; Intestinal thrombotic microangiopathy; Multiple myeloma; Stem cell transplantation; Ulcer

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CD79A ANTIGEN; CYCLOSPORIN A; EPSTEIN BARR VIRUS ENCODED SMALL RNA 1; FLUDARABINE; GANCICLOVIR; MELPHALAN; METHYLPREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CASE REPORT; ENTERITIS; EPITHELIUM CELL; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MELENA; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; STAINING; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULCER;

ANTIGENS, CD79; ENTERITIS; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; ILEUM; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; RNA, VIRAL; STEM CELL TRANSPLANTATION; ULCER;

EID: 33747480490     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2006.02001.x     Document Type: Article

References (32)

1. Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA. Non-myeloablative transplantation. Hematology 2002 (Am Soc Hematol Educ Program Book) 2002; 1: 392-421. Available from URL: http://www.asheducationbook.org/content/vol2002/ issue1/
2. Renga M, Pedrazzoli P, Siena S. Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. Ann Oncol 2003; 14: 1177-84.
3. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-9.
4. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980-87.
5. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-63.
6. Tiacci E, Luppi M, Barozzi P et al. Fatal herpesvirus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3-loci mismatched related donor. Haematologica 2000; 85: 94-7.
7. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 2003; 43: 78-84.
8. Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22: 351-7.
9. George JN, Selby GB. Thrombotic microangiopathy after allogeneic bone marrow transplantation: A pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant 2004; 33: 1073-4.
10. Nishida T, Hamaguchi M, Hirabayashi N et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: A clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143-50.
11. Hirabayashi N. Biopsy diagnosis of the ischemic enterocolitis associated with thrombotic microangiopathy. Ketsueki Shuyouka 2000; 41: 428-37 (in Japanese).
12. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
13. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-60.
14. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8.
15. Kajiwara M, Yamaguchi Y, Hirai K, Yata J. Increased urinary excretion of human cytomegalovirus in children with malignancy: Detection by polymerase chain reaction. Acta Paediatr Jpn 1993; 35: 387-93.
16. Van Camp B, Durie BG, Spier C et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377-82.
17. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94: 2208-16.
18. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JM, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001; 264-9.
19. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-65.
20. Snyder MJ, Stenzel TT, Buckley PJ et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004; 28: 794-800.
21. Ho AY, Adams S, Shaikh H, Pagliuca A, Devereux S, Mufti GJ. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant 2002; 29: 867-9.
22. Schubach WH, Hackman R, Neiman PE, Miller G, Thomas ED. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 1982; 60: 180-87.
23. Martin PJ, Shulman HM, Schubach WH et al. Fatal Epstein-Barr-virus- associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med 1984; 101: 310-15.
24. Gerritsen EJ, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377-82.
25. Zamkoff KW, Bergman S, Beaty MW. Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant. Bone Marrow Transplant 2003; 31: 219-22.
26. Milpied N, Coste-Burel M, Accard F et al. Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 23: 629-30.
27. Harada S, Kamata Y, Ishii Y et al. Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immunol 2004; 11: 123-30.
28. Narimatsu H, Kami M, Hara S et al. Intestinal thrombotic microangiopathy following reduced-intensity umbilical cord blood transplantation. Bone Marrow Transplant 2005; 36: 517-23.
29. McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation. Part I. Gastroenterology 1986; 90: 460-77.
30. Ziring D, Tran R, Edelstein S et al. Infectious enteritis after intestinal transplantation: Incidence, timing, and outcome. Transplant Proc 2004; 36: 379-80.
31. Yanai H, Shimizu N, Nagasaki S, Mitani N, Okita K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1582-6.
32. Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 2000; 157: 51-7.